Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00855205 · ClinicalTrials.gov registry record · Phase 2
Rituximab for Pulmonary Sarcoidosis
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
NCT00855205 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 10 participants.
The verdict
NCT00855205, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
Study Summary
Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with refractory disease.
Interventions
- DRUG Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2009-07 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00855205
The ClinicalTrials.gov registry entry for NCT00855205 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Rituximab is the first listed.
NCT00855205 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00855205 about?
NCT00855205 is a clinical study titled "Rituximab for Pulmonary Sarcoidosis". Sarcoidosis is a inflammatory disease affecting many parts of the body, especially the lungs. While most patients do well, there is a group of patients who require continuous doses of prednisone or other drugs. The current study will determine the role of Rituximab as new agent for patients with ref...
What is the current status of trial NCT00855205?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2009-07. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00855205?
The interventions under investigation include: Rituximab (DRUG).
Who is sponsoring clinical trial NCT00855205?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.